Author + information
- Received March 27, 2020
- Revision received April 2, 2020
- Accepted April 6, 2020
- Published online July 15, 2020.
- Vinh Q. Chau, MD,
- Estefania Oliveros, MD,
- Kiran Mahmood, MD,
- Aditi Singhvi, MD,
- Anuradha Lala, MD∗ (, )
- Noah Moss, MD,
- Umesh Gidwani, MD,
- Donna M. Mancini, MD,
- Sean P. Pinney, MD and
- Aditya Parikh, MD
- Division of Cardiology, Department of Medicine, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York
- ↵∗Address for correspondence:
Dr. Anuradha Lala, Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York 10029.
As health systems worldwide grapple with the coronavirus disease-2019 (COVID-19) pandemic, patients with durable LVAD support represent a unique population at risk for the disease. This paper outlines the case of such a patient who developed COVID-19 complicated by a “cytokine storm” with severe acute respiratory distress syndrome and myocardial injury and describes the challenges that arose during management.
Dr. Pinney is a consultant for Abbott Laboratories, CareDx, Medtronic, and Procyrion. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, or patient consent where appropriate. For more information, visit the JACC: Case Reports author instructions page.
- Received March 27, 2020.
- Revision received April 2, 2020.
- Accepted April 6, 2020.
- 2020 The Authors